- $416.08m
- $421.58m
- $824.50m
Brief: Myriad Genetics Announces Pricing Of Upsized Offering Of Common Stock
Brief: Myriad Genetics Announces Proposed Offering Of $100 Million Of Shares Of Common Stock
Brief: Myriad Genetics Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
Brief: Myriad Genetics Q3 Operating Income USD -60.1 Million
Myriad Genetics Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Myriad Genetics Appoints Sam Raha As Chief Operating Officer
Myriad Genetics Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Qiagen And Myriad Genetics Partner To Advance Companion Diagnostics Development For Cancer
U.S. STOCKS ON THE MOVE-Tempest Therapeutics, Ally Financial, Phio Pharmaceuticals
U.S. STOCKS ON THE MOVE-Myriad Genetics, Arista Networks, DaVita
Myriad rises on new 4-year contract, pricing terms with UnitedHealthcare
Brief: Myriad Genetics Inc - On Oct 10, 2023, Agreed On New Long-Term Agreement With UnitedHealthcare
U.S. RESEARCH ROUNDUP-Alteryx, Axsome Therapeutics, Inogen
Myriad Genetics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Myriad Genetics Q2 Operating Income USD -113.7 Million
Myriad Genetics Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Myriad Genetics Inc Entered Into Credit Agreement With The Lenders On June 30
Brief: Myriad Genetics Announces Research Collaboration For Minimal Residual Disease Testing Platform
Brief: Myriad Genetics Adds Folate Receptor Alpha To Precise Oncology Solutions Portfolio